Qianjin Pharmaceutical Industry acquires equity of 2 subsidiaries to accelerate the integration of resources under its control.

Zhuzhou Qianjin Pharmaceutical Co., Ltd. has obtained approval from the China Securities Regulatory Commission to approve the company's acquisition of 28.92% equity of Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and 68.00% equity of Hunan Qianjin Xielig Pharmaceutical Co., Ltd. through the issuance of shares and payment of cash. This is the 14th registration-effective restructuring project approved by the Shanghai Stock Exchange this year. It is reported that this transaction will improve the equity of Zhuzhou Guotou Holding, and help enhance the quality and efficiency of state-owned assets. After the transaction is completed, the stake of Zhuzhou Guotou in the listed company will increase from 28.76% to 34.94%, which is beneficial for maintaining the stability of the governance and control of the listed company.